RiboBio

Guangzhou RiboBio Co., Ltd. (referred to as RiboBio), established in 2004, is a national torch plan key high-tech enterprise led by Nobel laureates and selectees of national major talent projects, with nucleic acid technology as its core. Based on oligonucleotide and mRNA technologies, RiboBio is dedicated to providing high-quality various oligonucleotide and mRNA products (including but not limited to ASO, siRNA, CpG, Aptamer, crRNA, tracrRNA, and mRNA). In addition, the company has established oligonucleotide CDMO service platforms and mRNA/LNP formulation development and manufacturing platforms that meet or exceed international standards, capable of providing one-stop oligonucleotide/mRNA CDMO services, as well as LNP formulation development and manufacturing services, for various stages of nucleic acid drug development (from early discovery, clinical development to commercialization). It has provided products or services to over 5,000 institutions at home and abroad, and has now become a well-known enterprise in the global nucleic acid drug CDMO field. RiboBio owns over 60 independent intellectual property nucleic acid technology inventions and has obtained qualifications such as the Guangdong Provincial Nucleic Acid Drug Engineering Laboratory, Guangdong Provincial Nucleic Acid Medicine Engineering Technology Research Center, and the oligonucleotide API production license issued by NMPA. The company adheres to the development philosophy of "Innovation for development, quality for the future, integrity for customers," and pursues "Never-stop innovation"!